The laminin–dystroglycan interaction is essential for muscle function: mutations that inactivate the enzymes involved in dystroglycan modification cause a group of muscular dystrophies known as the dystroglycanopathies [53–56]. This evidence concerns the gene DAG1 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.